Ghost Tree Capital’s BridgeBio Pharma BBIO Stock Holding History

Ghost Tree Capital’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$4.46M	Buy	175,000 +35,000	+25%	+$919K	1.35%	28
2024 Q2	$3.55M	Sell	140,000 -35,000	-20%	-$957K	1.11%	35
2024 Q1	$5.41M	Buy	175,000 +50,000	+40%	+$1.7M	1.5%	23
2023 Q4	$5.05M	Buy	125,000 +50,000	+67%	+$1.5M	1.65%	18
2023 Q3	$1.98M	Buy	75,000 +33,000	+79%	+$936K	0.65%	50
2023 Q2	$722K	Buy	42,000 +17,000	+68%	+$256K	0.24%	48
2023 Q1	$415K	Buy	+25,000	New	+$292K	0.12%	57

Other funds holding BBIO

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ghost Tree Capital's BBIO Position: Q3 2024 in Review

Ghost Tree Capital increased its BridgeBio Pharma (BBIO) stake by 25% in Q3 2024, buying an estimated $919K and bringing the position to 175,000 shares worth $4.46M. The position accounts for 1.35% of the portfolio, ranked #28.

Ghost Tree Capital first reported a position in BBIO in Q1 2023 and has held it in 7 quarters since. The position peaked at $5.41M in Q1 2024. 253 funds tracked by Wall St. Rank hold BBIO as of Q3 2024.

Ghost Tree Capital held 175,000 shares of BridgeBio Pharma worth $4.46M as of Q3 2024.
Ghost Tree Capital bought 35,000 BridgeBio Pharma shares in Q3 2024, an estimated $919K.
BridgeBio Pharma made up 1.35% of Ghost Tree Capital's portfolio in Q3 2024, its #28 holding.
Ghost Tree Capital first reported a position in BridgeBio Pharma in Q1 2023 and has held it in 7 quarters since.
Ghost Tree Capital's BridgeBio Pharma position peaked at $5.41M in Q1 2024.
253 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q3 2024.

Based on Ghost Tree Capital's 13F filing for Q3 2024, filed 14 Nov 2024.